What We're Reading: Page 205
Industry reads hand-picked by our editors
Jan 30, 2020
-
Bloomberg
Coronavirus Is No Ebola, and That Presents a Different Problem
-
Endpoints News
Sanofi polishes rare disease profile as Niemann-Pick drug scores promising PhII/III data — there's just one question
-
The Atlantic
We Don't Have Enough Face Masks
-
STAT
Walmart places a big bet on cheaper, less intimidating primary care
Jan 29, 2020
-
Reuters
OxyContin maker Purdue is 'Pharma Co X' in U.S. opioid kickback probe - sources
-
The New York Times
U.S. Accuses Harvard Scientist of Concealing Chinese Funding
-
Endpoints News
Eyeing a trio of trial initiations, Jim Wilson's gene therapy startup woos Bruce Goldsmith from Deerfield as CEO
-
Vantage
The cost to Astrazeneca of building Brilinta
Jan 28, 2020
-
The Wall Street Journal
Martin Shkreli, Associate Tried to Block Generic Versions of Drug, Lawsuit Claims
-
NPR
When Insurers Don't Cover Drugs, Prescriptions Often Go Unfilled
-
The Japan Times
Osaka University transplants iPS cell-based heart cells in world's first clinical trial
-
Reuters
Incyte's skin disease drug meets main goal in late-stage study
Jan 27, 2020
Jan 24, 2020
-
The Boston Globe
Insys founder gets five and a half years in jail for his role in fentanyl prescription scheme
-
The Washington Post
What must be done to head off the coronavirus threat
-
Reuters
Roche's Tecentriq fails trial in form of urothelial cancer
-
OneZero
What Happened to the Theranos Headquarters?
Jan 23, 2020
-
Bloomberg
Deadly Viruses Aren't Pharma's Top Priority. Why Not?
-
POLITICO
White House prepared short list to shake up HHS leadership
-
The Irish Times
Takeda overhauls Shire’s Irish structure to ease dividend payments
-
BioCentury
FDA, CMS veteran Shah named FDA deputy commissioner for medical and scientific affairs
Previous
